Piperlongumine selectively suppresses ABC-DLBCL through inhibition of NF-κB p65 subunit nuclear import

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Constitutive NF-κB activation is crucial for the survival of activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL).
• Existing NF-κB inhibitors lack specificity, leading to potential side effects.
• Targeting NF-κB offers a potential therapeutic strategy for ABC-DLBCL.

Purpose of the Study:

• To identify and characterize novel inhibitors of NF-κB signaling in ABC-DLBCL.
• To elucidate the mechanism of action of piperlongumine on NF-κB pathway.
• To evaluate the therapeutic potential of piperlongumine in ABC-DLBCL models.

Main Methods:

• In vitro assays to assess piperlongumine's binding to NF-κB p65 subunit.
• Reporter assays to measure NF-κB transcriptional activity.
• Cell proliferation and apoptosis assays in ABC-DLBCL cell lines.
• In silico analysis of p65 structure and piperlongumine interaction.

Main Results:

• Piperlongumine directly binds to the NF-κB p65 subunit, inhibiting its nuclear translocation.
• This inhibition leads to suppression of NF-κB reporter activity and target gene expression.
• A specific cysteine residue (Cys38) in p65 is critical for piperlongumine's inhibitory effect.
• Piperlongumine selectively induces apoptosis and inhibits proliferation in ABC-DLBCL cells.
• Piperlongumine demonstrated no toxicity to normal cells or animals in previous studies.

Conclusions:

• Piperlongumine represents a novel therapeutic agent targeting NF-κB signaling in ABC-DLBCL.
• Its specific mechanism involves direct binding to p65 and inhibition of nuclear import.
• Piperlongumine offers a promising, selective, and non-toxic approach for ABC-DLBCL treatment.